A year after opening its first ‘Empax’ centre in Leederville, Western Australia, Emyria Ltd (ASX:EMD) has opened a second – this time within the eminent mental health hospital, the Perth Clinic.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Emyria aims to expand its provision of programs supporting patients with PTSD and treatment-resistant depression – including through psychedelic-assisted therapies – by 50%.
The first two fully funded patients will commence treatment on April 14, with this underscoring the activation of the Perth Clinic site and the company’s intention to roll out a broader strategy to meet clinical demand.
The latter also reflects structural changes in mental health care funding.
The centre’s location in a licensed facility is to ensure Emyria meets the requirements of payers set to fund Empax treatment. The company is now looking to potential expansion of ‘Empax’ into the eastern states.
“We are responding to growing patient demand and the expectations of major health funders,” Emyria executive chair Greg Hutchinson explained.
He continued: “Our expansion into licensed hospital settings demonstrates Emyria’s capacity to deliver scalable, evidence-based mental health care treatments.”
EMD has been at 3cps – a rise of 3.45% since the market opened today.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
